PLRX Stock Risk & Deep Value Analysis

Pliant Therapeutics Inc

Healthcare • Biotechnology

DVR Score

3.2

out of 10

Risk Trap

The Bottom Line on PLRX

We analyzed Pliant Therapeutics Inc using our deep value framework. Sign in to see our full verdict and DVR Score.

We ran PLRX through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Here's what we found.

Updated Mar 3, 2026•Run Fresh Analysis →

📈PLRX Performance Overview3yr weekly

📊

Unlock PLRX Performance Chart

See 3 years of price history, quarterly revenue trends, and DVR score changes

Weekly adjusted close · Quarterly revenue & EPS · DVR score history

PLRX Stock Risk Analysis

Overall Risk

Aggressive

Financial Risk

High

Market Risk

Medium

About Pliant Therapeutics Inc (PLRX)

Sector

Healthcare

Industry

Biotechnology

Market Cap Category

small

Market Cap

$100.68M

PLRX Deep Value Analysis

Pliant Therapeutics remains a deeply speculative, high-risk, high-reward investment following the INTEGRIS-IPF Phase 2b failure for bexotegrast. While the market capitalization has stabilized slightly at $0.08B from its previous low, the core investment thesis for broad market leadership is severely impaired. The 10x growth potential within 3-5 years hinges entirely on the successful and rapid execution of earlier-stage programs, specifically bexotegrast in Primary Sclerosing Cholangitis (PSC) and the Novartis-partnered PLRX-1001. Financial risk is critically high due to limited cash runway and anticipated future dilution. The proprietary integrin inhibitor platform and existing partnership offer a foundational moat, but the path to significant market share is now narrow and fraught with clinical and financial challenges, necessitating exceptional future milestones to justify a substantial re-rating.

Compare PLRX to Similar Stocks

See how Pliant Therapeutics Inc stacks up against related companies in our head-to-head analysis.

PLRX vs XBI

Compare →

PLRX vs ICPT

Compare →

PLRX Red Flags & Warning Signs

⚠
Negative or inconclusive data from ALPINE Phase 2a study in PSC
⚠
Significant equity dilution to fund ongoing operations
⚠
Termination or delays in the Novartis partnership
⚠
Emergence of competitive therapies in PSC or other target indications

Unlock PLRX Red Flags & Risk Warnings

Create a free account to see the full analysis

PLRX Financial Health Metrics

Market Cap

$100.68M

PLRX Competitive Moat Analysis

Moat Rating

Narrow

Moat Trend

Stable

Moat Sources

1 Identified

Intangible Assets/IP

The moat's durability hinges entirely on the clinical success of the remaining pipeline assets (bexotegrast in PSC, PLRX-1001). While the underlying integrin platform is proprietary, its commercial value is directly tied to successful drug development.

PLRX Competitive Moat Analysis

PLRX Catalysts & Growth Drivers

Near-Term (0-6 months)

•Q4 2025 Earnings Report (Estimated late March / early April 2026)
•Updates on ALPINE Phase 2a study enrollment and progress in PSC (Q2/Q3 2026)

Medium-Term (6-18 months)

•Potential interim or full data readout from ALPINE Phase 2a study in PSC (Estimated Q4 2026 / H1 2027)
•Progress updates on PLRX-1001 program with Novartis (e.g., Phase 1/2 initiation or data)

Long-Term (18+ months)

•Initiation of Phase 3 trial for bexotegrast in PSC or other fibrotic indications
•Expansion of proprietary integrin inhibitor platform to new therapeutic areas

Catalysts & Growth Drivers

Upgrade to Premium to see catalysts

PLRX Bull Case: What Could Go Right

✓
Positive Phase 2a ALPINE data in PSC (efficacy and safety)
✓
Securing non-dilutive financing or new strategic partnerships
✓
Significant extension of cash runway
✓
Any signs of progress or data from the PLRX-1001 (Novartis) program

Bull Case Analysis

See what could go right with Premium

🔔

Never miss a move on PLRX

Create a free account to set price alerts and get notified on Telegram when PLRX hits your targets.

📊 Explore More Stock Analysis

Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential.

Analyze Any Stock →View Top 100 Deep Value Stocks →

FAQ

What is the DVR Score for Pliant Therapeutics Inc (PLRX)?

As of March 3, 2026, Pliant Therapeutics Inc has a DVR Score of 3.2 out of 10, placing it in the "Risk Trap" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.

What is the market capitalization of Pliant Therapeutics Inc?

Pliant Therapeutics Inc's market capitalization is approximately $100.7M. The company operates in the Healthcare sector within the Biotechnology industry.

What ticker symbol does Pliant Therapeutics Inc use?

PLRX is the ticker symbol for Pliant Therapeutics Inc. The company trades on the NMS.

What is the risk level for PLRX stock?

Our analysis rates Pliant Therapeutics Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.

How often is the PLRX DVR analysis updated?

Our AI-powered analysis of Pliant Therapeutics Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on March 3, 2026.

Important Disclaimer – Not Financial Advice

Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.

All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research and consult with a qualified financial advisor.